CVSA · Covista Inc.
$125.48
+2.16 (+1.75%)
At close · Oct 2
Return incl. dividend (before tax)
Market Cap
$4.18B
Shares
34.04M
Volume · Oct 2
296.5K
Avg daily vol (3M)
360.95K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$125.48
Open$125.17
Day$124.28–126.96
52W close$89.36–153.98
Avg vol 30d364K
Short int1.9M · 5.7% float · 6.5d
Short vol82%
Last earningsOct 29, 2026
DataJan 2020–Oct 2026
Filing10-K · Aug 6
Up next
Next earnings call
Oct 29, 2026
Scheduled
· in 3 wks
filed Aug 6, 2026
call held Jan 28, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
-16.3%
Trailing year
Short interest
5.7%
Latest settlement · 6.5 days to cover
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Strong
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+7%
above
Price vs 50-day avg
−2%
below
RSI (14)
50
neutral
MACD trend
Positive
52-week position
56%
mid-range
Momentum
relative strength
1-month return
−2%
trailing
6-month return
+11%
trailing
YTD return
+21%
this year
Relative strength
−1%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $128 › 200d $117 — 50d above 200d
Institutional flow
Accumulating
2 of 378 funds reported for Sep 30 · net +459 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.69% of float · ▲ +9.4% MoM · 6.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
378 holders — mid 3-yr range
Squeeze score
66
elevated · 0–100
Fundamentals
Revenue growth
+9%
Y/Y
EPS growth
+14%
Y/Y
Free cash flow
$392.7M
Valuation
P/E 17.4
in line
Buyback
$661.8M
remaining
Balance sheet
$256.5M
net debt
Quant / Vol
risk profile
Volatility
53%
annualized · 1-yr
Max drawdown
−42%
past year
ATR
3.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Prior guidance
period ended
· from the Earnings Call filed Dec 31, 2025
Revenue
· full-year
$1.9B – $1.94B
Adjusted EPS
· annual
$7.80 – $8.00
Guided vs delivered
· last 3 settled
Revenue
full-year
guided $1.9B – $1.94B
$1.95B
Beat +1.8%
Revenue
fiscal year 2024
guided $1.52B – $1.56B
$1.58B
Beat +2.9%
Revenue
fiscal year 2023
guided $1.4B – $1.45B
$1.45B
Beat +1.8%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+7%
Bullish
Price vs 50-day avg
−2%
Neutral
RSI (14)
50
Neutral
MACD trend
Positive
Bullish
52-week position
56%
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $128 › 200d $117 — 50d above 200d
Institutional flow
Accumulating
2 of 378 funds reported for Sep 30 · net +459 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.69% of float · ▲ +9.4% MoM · 6.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
378 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $89
Now $125 · 56%
Range high $154
vs 200-day avg +7%
vs 50-day avg -2%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted earnings per share non-GAAP | $8.25 | FY2026 | — |
GAAP → non-GAAP reconciliationGAAP Diluted earnings per share (GAAP) $7.04
+$0.18 Restructuring expense
+$0.31 Amortization of acquired intangible assets
+$0.52 Strategic advisory costs
+$0.13 Loss on debt extinguishment, litigation reserve, asset impairments, loss on assets held for sale, and debt modification costs
-$0.09 Tax benefit due to change in unrecognized tax benefits
-$0.29 Income tax impact on non-GAAP adjustments
+$0.44 Loss (income) from discontinued operations
= Adjusted earnings per share $8.25
|
|||
| Adjusted EBITDA non-GAAP | $521.7M | FY2026 | — |
| Adjusted EBITDA (non-GAAP) - Chamberlain non-GAAP | $185.53M | Year Ended June 30, 2026 | — |
| Adjusted EBITDA (non-GAAP) - Medical and Veterinary non-GAAP | $102.78M | Year Ended June 30, 2026 | — |
| Adjusted EBITDA (non-GAAP) - Walden non-GAAP | $267.96M | Year Ended June 30, 2026 | — |
| Adjusted EBITDA - Home Office non-GAAP | -$34.53M | Year Ended June 30, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Adjusted operating loss -$43.84M
+$658K Depreciation
+$8.66M Stock-based compensation
= Adjusted EBITDA - Home Office -$34.53M
|
|||
| Adjusted EBITDA margin non-GAAP | 25.3% | Q4 FY2026 | — |
| Adjusted EBITDA margin (non-GAAP) non-GAAP | 26.7% | Year Ended June 30, 2026 | — |
| Adjusted EBITDA margin (non-GAAP) - Chamberlain non-GAAP | 24.7% | Year Ended June 30, 2026 | — |
| Adjusted EBITDA margin (non-GAAP) - Medical and Veterinary non-GAAP | 25.8% | Year Ended June 30, 2026 | — |
| Adjusted EBITDA margin (non-GAAP) - Walden non-GAAP | 33.3% | Year Ended June 30, 2026 | — |
| Adjusted net income (non-GAAP) non-GAAP | $294.7M | Year Ended June 30, 2026 | — |
| Adjusted operating income (non-GAAP) non-GAAP | $419.49M | Year Ended June 30, 2026 | — |
| Adjusted operating loss non-GAAP | -$43.84M | fiscal year 2026 filing | — |
| Adjusted operating margin (non-GAAP) non-GAAP | 21.5% | Year Ended June 30, 2026 | — |
| Average cost per share repurchased | $98.35 | fiscal year 2026 filing | — |
| Average total student enrollment at Chamberlain | 1.1% | fiscal year 2026 filing | — |
| Average total student enrollment at the medical and veterinary schools | 4.5% | fiscal year 2026 filing | — |
| Average total student enrollment at Walden | 13.2% | fiscal year 2026 filing | — |
| Chamberlain Total Students | 39,501 | Q4 FY2026 | — |
| Diluted adjusted earnings per share (non-GAAP) non-GAAP | $8.25 | fiscal year 2026 filing | — |
| Free cash flow (non-GAAP) non-GAAP | $393.1M | Twelve Months Ended FY26 Q4 | — |
| Medical and Veterinary enrolled approximately 5,250 students on average | 5,250 | FY2026 | — |
| Medical and Veterinary Total Students | 5,120 | Q4 FY2026 | — |
| Net debt (non-GAAP) non-GAAP | $266.68M | Year Ended June 30, 2026 | — |
| Shares repurchased under share repurchase programs | 2,421,920 | fiscal year 2026 filing | — |
| Walden Total Students | 54,851 | Q4 FY2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Education & Training Services — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CVSA
this stock
Covista Inc.
|
$4.18B | +21.3% | +9.3% | 17.4 | 5.7% |
|
EDU
New Oriental Education & Technology Group Inc.
|
$8.75B | +0.7% | +15.5% | — | 2.0% |
|
TAL
TAL Education Group
|
$6.66B | +10.5% | +33.7% | — | 3.7% |
|
LAUR
Laureate Education, Inc.
|
$5.15B | +14.7% | +19.5% | 17.0 | 3.1% |
|
XXI
Twenty One Capital, Inc.
|
$3.96B | -24.7% | — | — | 1.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CVSA | +3.9% | -1.7% | +10.9% | +2.7% | +21.3% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | +4.1% | -1.2% | -1.3% | +1.8% | +8.4% |
Capital returns
Buyback program
· as of Jun 30, 2026
Authorized
$750.00M
Spent (derived)
$88.20M
Remaining
$661.80M
Spent
Remaining
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.